ABOUT US
CONTACT US
FAQ
PRIVACY POLICY
REFUND AND CANCELLATION
BLOGS
COMPANIES
REPORTS
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Automative
0
U.S. (TOLL FREE)
+1 (315) 215-3225
Global Live Attenuated Measles Vaccine Market Research Report 2025
Published Date: March 2025
|
Report Code: QYRE-Auto-3O15442
Home | Market Reports | Health| Health Conditions| Infectious Diseases
Global Live Attenuated Measles Vaccine Market Insights Forecast to 2029
BUY CHAPTERS

Global Live Attenuated Measles Vaccine Market Research Report 2025

Code: QYRE-Auto-3O15442
Report
March 2025
Pages:105
QYResearch
Buy Now with 15% Discount
DESCRIPTION
TABLE OF CONTENT
TABLES & FIGURES
FEATURED COMPANIES
GSK
Sanofi Pasteur
Bavarian Nordic
MedImmune
Johnson & Johnson
CSL Limited
Changchun Qijian Biological Products Co., Ltd
Beijing Institute of Biological Products Co., Ltd.
Wuhan Institute of Biological Products Co Ltd
Shanghai Institute of Biological Products Co., Ltd.
Lanzhou Institute of Biological Products Co., Ltd
Emergent Biosolutions
Novartis
Serum Institute of India
Pfizer Inc
Merck

Live Attenuated Measles Vaccine Market Size

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years.

Live Attenuated Measles Vaccine Market

Live Attenuated Measles Vaccine Market

The global market for Live Attenuated Measles Vaccine was valued at US$ million in the year 2024 and is projected to reach a revised size of US$ million by 2031, growing at a CAGR of %during the forecast period.
The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Live Attenuated Measles Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Live Attenuated Measles Vaccine.
The Live Attenuated Measles Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Units) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Live Attenuated Measles Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Live Attenuated Measles Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Live Attenuated Measles Vaccine Market Report

Report Metric Details
Report Name Live Attenuated Measles Vaccine Market
CAGR 5%
Segment by Type
  • Liquid
  • Powder
Segment by Application
  • Hospital
  • Clinic
Consumption by Region
  • North America (United States, Canada)
  • Europe (Germany, France, UK, Italy, Russia)
  • Asia-Pacific (China, Japan, South Korea, Taiwan)
  • Southeast Asia (India)
  • Latin America (Mexico, Brazil)
By Company GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic, Medimmune, Johnson & Johnson, CSL Limited, Changchun Qijian Biological Products Co., Ltd, Beijing Institute of Biological Products Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd
Forecast units USD million in value
Report coverage Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

  • Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
  • Chapter 2: Detailed analysis of Live Attenuated Measles Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
  • Chapter 3: Sales, revenue of Live Attenuated Measles Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
  • Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
  • Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
  • Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
  • Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
  • Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
  • Chapter 9: The main points and conclusions of the report. 

FAQ for this report

Who are the main players in the Live Attenuated Measles Vaccine Market report?

Ans: The main players in the Live Attenuated Measles Vaccine Market are GSK, Sanofi-Pasteur, Merck, Pfizer, Serum Institute of India, Novartis, Emergent Biosolutions, Bavarian Nordic, Medimmune, Johnson & Johnson, CSL Limited, Changchun Qijian Biological Products Co., Ltd, Beijing Institute of Biological Products Co., Ltd, Wuhan Institute of Biological Products Co., Ltd, Shanghai Institute of Biological Products Co., Ltd, Lanzhou Institute of Biological Products Co., Ltd

What are the Application segmentation covered in the Live Attenuated Measles Vaccine Market report?

Ans: The Applications covered in the Live Attenuated Measles Vaccine Market report are Hospital, Clinic

What are the Type segmentation covered in the Live Attenuated Measles Vaccine Market report?

Ans: The Types covered in the Live Attenuated Measles Vaccine Market report are Liquid, Powder

Recommended Reports

Vaccine Markets

Measles & Related

Delivery & Devices

1 Live Attenuated Measles Vaccine Market Overview
1.1 Product Definition
1.2 Live Attenuated Measles Vaccine by Type
1.2.1 Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2024 VS 2031)
1.2.2 Liquid
1.2.3 Powder
1.3 Live Attenuated Measles Vaccine by Application
1.3.1 Global Live Attenuated Measles Vaccine Market Value by Application (2024 VS 2031)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Live Attenuated Measles Vaccine Market Size Estimates and Forecasts
1.4.1 Global Live Attenuated Measles Vaccine Revenue 2020-2031
1.4.2 Global Live Attenuated Measles Vaccine Sales 2020-2031
1.4.3 Global Live Attenuated Measles Vaccine Market Average Price (2020-2031)
1.5 Assumptions and Limitations
2 Live Attenuated Measles Vaccine Market Competition by Manufacturers
2.1 Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2020-2025)
2.2 Global Live Attenuated Measles Vaccine Revenue Market Share by Manufacturers (2020-2025)
2.3 Global Live Attenuated Measles Vaccine Average Price by Manufacturers (2020-2025)
2.4 Global Key Players of Live Attenuated Measles Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
2.7 Global Key Manufacturers of Live Attenuated Measles Vaccine, Date of Enter into This Industry
2.8 Global Live Attenuated Measles Vaccine Market Competitive Situation and Trends
2.8.1 Global Live Attenuated Measles Vaccine Market Concentration Rate
2.8.2 The Global 5 and 10 Largest Live Attenuated Measles Vaccine Players Market Share by Revenue
2.8.3 Global Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
2.9 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Global Live Attenuated Measles Vaccine Market Scenario by Region
3.1 Global Live Attenuated Measles Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031
3.2 Global Live Attenuated Measles Vaccine Sales by Region: 2020-2031
3.2.1 Global Live Attenuated Measles Vaccine Sales by Region: 2020-2025
3.2.2 Global Live Attenuated Measles Vaccine Sales by Region: 2026-2031
3.3 Global Live Attenuated Measles Vaccine Revenue by Region: 2020-2031
3.3.1 Global Live Attenuated Measles Vaccine Revenue by Region: 2020-2025
3.3.2 Global Live Attenuated Measles Vaccine Revenue by Region: 2026-2031
3.4 North America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.4.1 North America Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.4.2 North America Live Attenuated Measles Vaccine Sales by Country (2020-2031)
3.4.3 North America Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
3.4.4 United States
3.4.5 Canada
3.5 Europe Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.5.1 Europe Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.5.2 Europe Live Attenuated Measles Vaccine Sales by Country (2020-2031)
3.5.3 Europe Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Live Attenuated Measles Vaccine Market Facts & Figures by Region
3.6.1 Asia Pacific Live Attenuated Measles Vaccine Market Size by Region: 2020 VS 2024 VS 2031
3.6.2 Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2020-2031)
3.6.3 Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2020-2031)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Southeast Asia
3.7 Latin America Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.7.1 Latin America Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.7.2 Latin America Live Attenuated Measles Vaccine Sales by Country (2020-2031)
3.7.3 Latin America Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Live Attenuated Measles Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Live Attenuated Measles Vaccine Market Size by Country: 2020 VS 2024 VS 2031
3.8.2 Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2020-2031)
3.8.3 Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2020-2031)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Live Attenuated Measles Vaccine Sales by Type (2020-2031)
4.1.1 Global Live Attenuated Measles Vaccine Sales by Type (2020-2025)
4.1.2 Global Live Attenuated Measles Vaccine Sales by Type (2026-2031)
4.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Type (2020-2031)
4.2 Global Live Attenuated Measles Vaccine Revenue by Type (2020-2031)
4.2.1 Global Live Attenuated Measles Vaccine Revenue by Type (2020-2025)
4.2.2 Global Live Attenuated Measles Vaccine Revenue by Type (2026-2031)
4.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2020-2031)
4.3 Global Live Attenuated Measles Vaccine Price by Type (2020-2031)
5 Segment by Application
5.1 Global Live Attenuated Measles Vaccine Sales by Application (2020-2031)
5.1.1 Global Live Attenuated Measles Vaccine Sales by Application (2020-2025)
5.1.2 Global Live Attenuated Measles Vaccine Sales by Application (2026-2031)
5.1.3 Global Live Attenuated Measles Vaccine Sales Market Share by Application (2020-2031)
5.2 Global Live Attenuated Measles Vaccine Revenue by Application (2020-2031)
5.2.1 Global Live Attenuated Measles Vaccine Revenue by Application (2020-2025)
5.2.2 Global Live Attenuated Measles Vaccine Revenue by Application (2026-2031)
5.2.3 Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2020-2031)
5.3 Global Live Attenuated Measles Vaccine Price by Application (2020-2031)
6 Key Companies Profiled
6.1 GSK
6.1.1 GSK Company Information
6.1.2 GSK Description and Business Overview
6.1.3 GSK Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.1.4 GSK Live Attenuated Measles Vaccine Product Portfolio
6.1.5 GSK Recent Developments/Updates
6.2 Sanofi-Pasteur
6.2.1 Sanofi-Pasteur Company Information
6.2.2 Sanofi-Pasteur Description and Business Overview
6.2.3 Sanofi-Pasteur Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.2.4 Sanofi-Pasteur Live Attenuated Measles Vaccine Product Portfolio
6.2.5 Sanofi-Pasteur Recent Developments/Updates
6.3 Merck
6.3.1 Merck Company Information
6.3.2 Merck Description and Business Overview
6.3.3 Merck Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.3.4 Merck Live Attenuated Measles Vaccine Product Portfolio
6.3.5 Merck Recent Developments/Updates
6.4 Pfizer
6.4.1 Pfizer Company Information
6.4.2 Pfizer Description and Business Overview
6.4.3 Pfizer Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.4.4 Pfizer Live Attenuated Measles Vaccine Product Portfolio
6.4.5 Pfizer Recent Developments/Updates
6.5 Serum Institute of India
6.5.1 Serum Institute of India Company Information
6.5.2 Serum Institute of India Description and Business Overview
6.5.3 Serum Institute of India Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.5.4 Serum Institute of India Live Attenuated Measles Vaccine Product Portfolio
6.5.5 Serum Institute of India Recent Developments/Updates
6.6 Novartis
6.6.1 Novartis Company Information
6.6.2 Novartis Description and Business Overview
6.6.3 Novartis Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.6.4 Novartis Live Attenuated Measles Vaccine Product Portfolio
6.6.5 Novartis Recent Developments/Updates
6.7 Emergent Biosolutions
6.7.1 Emergent Biosolutions Company Information
6.7.2 Emergent Biosolutions Description and Business Overview
6.7.3 Emergent Biosolutions Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.7.4 Emergent Biosolutions Live Attenuated Measles Vaccine Product Portfolio
6.7.5 Emergent Biosolutions Recent Developments/Updates
6.8 Bavarian Nordic
6.8.1 Bavarian Nordic Company Information
6.8.2 Bavarian Nordic Description and Business Overview
6.8.3 Bavarian Nordic Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.8.4 Bavarian Nordic Live Attenuated Measles Vaccine Product Portfolio
6.8.5 Bavarian Nordic Recent Developments/Updates
6.9 Medimmune
6.9.1 Medimmune Company Information
6.9.2 Medimmune Description and Business Overview
6.9.3 Medimmune Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.9.4 Medimmune Live Attenuated Measles Vaccine Product Portfolio
6.9.5 Medimmune Recent Developments/Updates
6.10 Johnson & Johnson
6.10.1 Johnson & Johnson Company Information
6.10.2 Johnson & Johnson Description and Business Overview
6.10.3 Johnson & Johnson Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.10.4 Johnson & Johnson Live Attenuated Measles Vaccine Product Portfolio
6.10.5 Johnson & Johnson Recent Developments/Updates
6.11 CSL Limited
6.11.1 CSL Limited Company Information
6.11.2 CSL Limited Description and Business Overview
6.11.3 CSL Limited Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.11.4 CSL Limited Live Attenuated Measles Vaccine Product Portfolio
6.11.5 CSL Limited Recent Developments/Updates
6.12 Changchun Qijian Biological Products Co., Ltd
6.12.1 Changchun Qijian Biological Products Co., Ltd Company Information
6.12.2 Changchun Qijian Biological Products Co., Ltd Description and Business Overview
6.12.3 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.12.4 Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.12.5 Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
6.13 Beijing Institute of Biological Products Co., Ltd
6.13.1 Beijing Institute of Biological Products Co., Ltd Company Information
6.13.2 Beijing Institute of Biological Products Co., Ltd Description and Business Overview
6.13.3 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.13.4 Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.13.5 Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
6.14 Wuhan Institute of Biological Products Co., Ltd
6.14.1 Wuhan Institute of Biological Products Co., Ltd Company Information
6.14.2 Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
6.14.3 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.14.4 Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.14.5 Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
6.15 Shanghai Institute of Biological Products Co., Ltd
6.15.1 Shanghai Institute of Biological Products Co., Ltd Company Information
6.15.2 Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
6.15.3 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.15.4 Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.15.5 Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
6.16 Lanzhou Institute of Biological Products Co., Ltd
6.16.1 Lanzhou Institute of Biological Products Co., Ltd Company Information
6.16.2 Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
6.16.3 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales, Revenue and Gross Margin (2020-2025)
6.16.4 Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product Portfolio
6.16.5 Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Live Attenuated Measles Vaccine Industry Chain Analysis
7.2 Live Attenuated Measles Vaccine Raw Material Supply Analysis
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Live Attenuated Measles Vaccine Production Mode & Process Analysis
7.4 Live Attenuated Measles Vaccine Sales and Marketing
7.4.1 Live Attenuated Measles Vaccine Sales Channels
7.4.2 Live Attenuated Measles Vaccine Distributors
7.5 Live Attenuated Measles Vaccine Customer Analysis
8 Live Attenuated Measles Vaccine Market Dynamics
8.1 Live Attenuated Measles Vaccine Industry Trends
8.2 Live Attenuated Measles Vaccine Market Drivers
8.3 Live Attenuated Measles Vaccine Market Challenges
8.4 Live Attenuated Measles Vaccine Market Restraints
9 Research Findings and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
FEATURED COMPANIES
GSK
Sanofi Pasteur
Bavarian Nordic
MedImmune
Johnson & Johnson
CSL Limited
Changchun Qijian Biological Products Co., Ltd
Beijing Institute of Biological Products Co., Ltd.
Wuhan Institute of Biological Products Co Ltd
Shanghai Institute of Biological Products Co., Ltd.
Lanzhou Institute of Biological Products Co., Ltd
Emergent Biosolutions
Novartis
Serum Institute of India
Pfizer Inc
Merck
List of Tables
 Table 1. Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)
 Table 2. Global Live Attenuated Measles Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)
 Table 3. Global Live Attenuated Measles Vaccine Market Competitive Situation by Manufacturers in 2024
 Table 4. Global Live Attenuated Measles Vaccine Sales (K Units) of Key Manufacturers (2020-2025)
 Table 5. Global Live Attenuated Measles Vaccine Sales Market Share by Manufacturers (2020-2025)
 Table 6. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)
 Table 7. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers (2020-2025)
 Table 8. Global Market Live Attenuated Measles Vaccine Average Price (US$/Unit) of Key Manufacturers (2020-2025)
 Table 9. Global Key Players of Live Attenuated Measles Vaccine, Industry Ranking, 2022 VS 2023 VS 2024
 Table 10. Global Key Manufacturers of Live Attenuated Measles Vaccine, Manufacturing Sites & Headquarters
 Table 11. Global Key Manufacturers of Live Attenuated Measles Vaccine, Product Type & Application
 Table 12. Global Key Manufacturers of Live Attenuated Measles Vaccine, Date of Enter into This Industry
 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)
 Table 14. Global Live Attenuated Measles Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Live Attenuated Measles Vaccine as of 2024)
 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans
 Table 16. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Table 17. Global Live Attenuated Measles Vaccine Sales by Region (2020-2025) & (K Units)
 Table 18. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2020-2025)
 Table 19. Global Live Attenuated Measles Vaccine Sales by Region (2026-2031) & (K Units)
 Table 20. Global Live Attenuated Measles Vaccine Sales Market Share by Region (2026-2031)
 Table 21. Global Live Attenuated Measles Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 22. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2020-2025)
 Table 23. Global Live Attenuated Measles Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 24. Global Live Attenuated Measles Vaccine Revenue Market Share by Region (2026-2031)
 Table 25. North America Live Attenuated Measles Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 26. North America Live Attenuated Measles Vaccine Sales by Country (2020-2025) & (K Units)
 Table 27. North America Live Attenuated Measles Vaccine Sales by Country (2026-2031) & (K Units)
 Table 28. North America Live Attenuated Measles Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 29. North America Live Attenuated Measles Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 30. Europe Live Attenuated Measles Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 31. Europe Live Attenuated Measles Vaccine Sales by Country (2020-2025) & (K Units)
 Table 32. Europe Live Attenuated Measles Vaccine Sales by Country (2026-2031) & (K Units)
 Table 33. Europe Live Attenuated Measles Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 34. Europe Live Attenuated Measles Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 35. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)
 Table 36. Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2020-2025) & (K Units)
 Table 37. Asia Pacific Live Attenuated Measles Vaccine Sales by Region (2026-2031) & (K Units)
 Table 38. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2020-2025) & (US$ Million)
 Table 39. Asia Pacific Live Attenuated Measles Vaccine Revenue by Region (2026-2031) & (US$ Million)
 Table 40. Latin America Live Attenuated Measles Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 41. Latin America Live Attenuated Measles Vaccine Sales by Country (2020-2025) & (K Units)
 Table 42. Latin America Live Attenuated Measles Vaccine Sales by Country (2026-2031) & (K Units)
 Table 43. Latin America Live Attenuated Measles Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 44. Latin America Live Attenuated Measles Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 45. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)
 Table 46. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2020-2025) & (K Units)
 Table 47. Middle East and Africa Live Attenuated Measles Vaccine Sales by Country (2026-2031) & (K Units)
 Table 48. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2020-2025) & (US$ Million)
 Table 49. Middle East and Africa Live Attenuated Measles Vaccine Revenue by Country (2026-2031) & (US$ Million)
 Table 50. Global Live Attenuated Measles Vaccine Sales (K Units) by Type (2020-2025)
 Table 51. Global Live Attenuated Measles Vaccine Sales (K Units) by Type (2026-2031)
 Table 52. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2020-2025)
 Table 53. Global Live Attenuated Measles Vaccine Sales Market Share by Type (2026-2031)
 Table 54. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Type (2020-2025)
 Table 55. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Type (2026-2031)
 Table 56. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2020-2025)
 Table 57. Global Live Attenuated Measles Vaccine Revenue Market Share by Type (2026-2031)
 Table 58. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2020-2025)
 Table 59. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2026-2031)
 Table 60. Global Live Attenuated Measles Vaccine Sales (K Units) by Application (2020-2025)
 Table 61. Global Live Attenuated Measles Vaccine Sales (K Units) by Application (2026-2031)
 Table 62. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2020-2025)
 Table 63. Global Live Attenuated Measles Vaccine Sales Market Share by Application (2026-2031)
 Table 64. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Application (2020-2025)
 Table 65. Global Live Attenuated Measles Vaccine Revenue (US$ Million) by Application (2026-2031)
 Table 66. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2020-2025)
 Table 67. Global Live Attenuated Measles Vaccine Revenue Market Share by Application (2026-2031)
 Table 68. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2020-2025)
 Table 69. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2026-2031)
 Table 70. GSK Company Information
 Table 71. GSK Description and Business Overview
 Table 72. GSK Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 73. GSK Live Attenuated Measles Vaccine Product
 Table 74. GSK Recent Developments/Updates
 Table 75. Sanofi-Pasteur Company Information
 Table 76. Sanofi-Pasteur Description and Business Overview
 Table 77. Sanofi-Pasteur Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 78. Sanofi-Pasteur Live Attenuated Measles Vaccine Product
 Table 79. Sanofi-Pasteur Recent Developments/Updates
 Table 80. Merck Company Information
 Table 81. Merck Description and Business Overview
 Table 82. Merck Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 83. Merck Live Attenuated Measles Vaccine Product
 Table 84. Merck Recent Developments/Updates
 Table 85. Pfizer Company Information
 Table 86. Pfizer Description and Business Overview
 Table 87. Pfizer Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 88. Pfizer Live Attenuated Measles Vaccine Product
 Table 89. Pfizer Recent Developments/Updates
 Table 90. Serum Institute of India Company Information
 Table 91. Serum Institute of India Description and Business Overview
 Table 92. Serum Institute of India Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 93. Serum Institute of India Live Attenuated Measles Vaccine Product
 Table 94. Serum Institute of India Recent Developments/Updates
 Table 95. Novartis Company Information
 Table 96. Novartis Description and Business Overview
 Table 97. Novartis Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 98. Novartis Live Attenuated Measles Vaccine Product
 Table 99. Novartis Recent Developments/Updates
 Table 100. Emergent Biosolutions Company Information
 Table 101. Emergent Biosolutions Description and Business Overview
 Table 102. Emergent Biosolutions Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 103. Emergent Biosolutions Live Attenuated Measles Vaccine Product
 Table 104. Emergent Biosolutions Recent Developments/Updates
 Table 105. Bavarian Nordic Company Information
 Table 106. Bavarian Nordic Description and Business Overview
 Table 107. Bavarian Nordic Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 108. Bavarian Nordic Live Attenuated Measles Vaccine Product
 Table 109. Bavarian Nordic Recent Developments/Updates
 Table 110. Medimmune Company Information
 Table 111. Medimmune Description and Business Overview
 Table 112. Medimmune Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 113. Medimmune Live Attenuated Measles Vaccine Product
 Table 114. Medimmune Recent Developments/Updates
 Table 115. Johnson & Johnson Company Information
 Table 116. Johnson & Johnson Description and Business Overview
 Table 117. Johnson & Johnson Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 118. Johnson & Johnson Live Attenuated Measles Vaccine Product
 Table 119. Johnson & Johnson Recent Developments/Updates
 Table 120. CSL Limited Company Information
 Table 121. CSL Limited Description and Business Overview
 Table 122. CSL Limited Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 123. CSL Limited Live Attenuated Measles Vaccine Product
 Table 124. CSL Limited Recent Developments/Updates
 Table 125. Changchun Qijian Biological Products Co., Ltd Company Information
 Table 126. Changchun Qijian Biological Products Co., Ltd Description and Business Overview
 Table 127. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 128. Changchun Qijian Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
 Table 129. Changchun Qijian Biological Products Co., Ltd Recent Developments/Updates
 Table 130. Beijing Institute of Biological Products Co., Ltd Company Information
 Table 131. Beijing Institute of Biological Products Co., Ltd Description and Business Overview
 Table 132. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 133. Beijing Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
 Table 134. Beijing Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 135. Wuhan Institute of Biological Products Co., Ltd Company Information
 Table 136. Wuhan Institute of Biological Products Co., Ltd Description and Business Overview
 Table 137. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 138. Wuhan Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
 Table 139. Wuhan Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 140. Shanghai Institute of Biological Products Co., Ltd Company Information
 Table 141. Shanghai Institute of Biological Products Co., Ltd Description and Business Overview
 Table 142. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 143. Shanghai Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
 Table 144. Shanghai Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 145. Lanzhou Institute of Biological Products Co., Ltd Company Information
 Table 146. Lanzhou Institute of Biological Products Co., Ltd Description and Business Overview
 Table 147. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2020-2025)
 Table 148. Lanzhou Institute of Biological Products Co., Ltd Live Attenuated Measles Vaccine Product
 Table 149. Lanzhou Institute of Biological Products Co., Ltd Recent Developments/Updates
 Table 150. Key Raw Materials Lists
 Table 151. Raw Materials Key Suppliers Lists
 Table 152. Live Attenuated Measles Vaccine Distributors List
 Table 153. Live Attenuated Measles Vaccine Customers List
 Table 154. Live Attenuated Measles Vaccine Market Trends
 Table 155. Live Attenuated Measles Vaccine Market Drivers
 Table 156. Live Attenuated Measles Vaccine Market Challenges
 Table 157. Live Attenuated Measles Vaccine Market Restraints
 Table 158. Research Programs/Design for This Report
 Table 159. Key Data Information from Secondary Sources
 Table 160. Key Data Information from Primary Sources
 Table 161. Authors List of This Report


List of Figures
 Figure 1. Product Picture of Live Attenuated Measles Vaccine
 Figure 2. Global Live Attenuated Measles Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)
 Figure 3. Global Live Attenuated Measles Vaccine Market Share by Type: 2024 & 2031
 Figure 4. Liquid Product Picture
 Figure 5. Powder Product Picture
 Figure 6. Global Live Attenuated Measles Vaccine Market Value by Application (2020-2031) & (US$ Million)
 Figure 7. Global Live Attenuated Measles Vaccine Market Share by Application: 2024 & 2031
 Figure 8. Hospital
 Figure 9. Clinic
 Figure 10. Global Live Attenuated Measles Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031
 Figure 11. Global Live Attenuated Measles Vaccine Market Size (2020-2031) & (US$ Million)
 Figure 12. Global Live Attenuated Measles Vaccine Sales (2020-2031) & (K Units)
 Figure 13. Global Live Attenuated Measles Vaccine Average Price (US$/Unit) & (2020-2031)
 Figure 14. Live Attenuated Measles Vaccine Report Years Considered
 Figure 15. Live Attenuated Measles Vaccine Sales Share by Manufacturers in 2024
 Figure 16. Global Live Attenuated Measles Vaccine Revenue Share by Manufacturers in 2024
 Figure 17. Global 5 and 10 Largest Live Attenuated Measles Vaccine Players: Market Share by Revenue in Live Attenuated Measles Vaccine in 2024
 Figure 18. Live Attenuated Measles Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024
 Figure 19. Global Live Attenuated Measles Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031
 Figure 20. North America Live Attenuated Measles Vaccine Sales Market Share by Country (2020-2031)
 Figure 21. North America Live Attenuated Measles Vaccine Revenue Market Share by Country (2020-2031)
 Figure 22. United States Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 23. Canada Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 24. Europe Live Attenuated Measles Vaccine Sales Market Share by Country (2020-2031)
 Figure 25. Europe Live Attenuated Measles Vaccine Revenue Market Share by Country (2020-2031)
 Figure 26. Germany Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 27. France Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 28. U.K. Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 29. Italy Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 30. Russia Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 31. Asia Pacific Live Attenuated Measles Vaccine Sales Market Share by Region (2020-2031)
 Figure 32. Asia Pacific Live Attenuated Measles Vaccine Revenue Market Share by Region (2020-2031)
 Figure 33. China Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 34. Japan Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 35. South Korea Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 36. India Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 37. Australia Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 38. China Taiwan Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 39. Southeast Asia Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 40. Latin America Live Attenuated Measles Vaccine Sales Market Share by Country (2020-2031)
 Figure 41. Latin America Live Attenuated Measles Vaccine Revenue Market Share by Country (2020-2031)
 Figure 42. Mexico Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 43. Brazil Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 44. Argentina Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 45. Middle East and Africa Live Attenuated Measles Vaccine Sales Market Share by Country (2020-2031)
 Figure 46. Middle East and Africa Live Attenuated Measles Vaccine Revenue Market Share by Country (2020-2031)
 Figure 47. Turkey Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 48. Saudi Arabia Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 49. UAE Live Attenuated Measles Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)
 Figure 50. Global Sales Market Share of Live Attenuated Measles Vaccine by Type (2020-2031)
 Figure 51. Global Revenue Market Share of Live Attenuated Measles Vaccine by Type (2020-2031)
 Figure 52. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Type (2020-2031)
 Figure 53. Global Sales Market Share of Live Attenuated Measles Vaccine by Application (2020-2031)
 Figure 54. Global Revenue Market Share of Live Attenuated Measles Vaccine by Application (2020-2031)
 Figure 55. Global Live Attenuated Measles Vaccine Price (US$/Unit) by Application (2020-2031)
 Figure 56. Live Attenuated Measles Vaccine Value Chain
 Figure 57. Channels of Distribution (Direct Vs Distribution)
 Figure 58. Bottom-up and Top-down Approaches for This Report
 Figure 59. Data Triangulation
 Figure 60. Key Executives Interviewed
SELECT A FORMAT
Added to Cart
Electronic (PDF)

$2900

This license allows only one user to access the PDF.
Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together
Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report
Add to Cart
Buy Now (15% Discount)
INQUIRE FOR DISCOUNT

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

Lukasiewicz Research Network

SIMILAR REPORTS

Global Measles Combined with Live Attenuated Vaccine Market Research Report 2025
Global Attenuated Vaccine Market Research Report 2025
Live Attenuated Herpes Zoster Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Live Attenuated Vaccine for Chickenpox Market Research Report 2025
Global Attenuated Vaccine for Human Rabies Market Research Report 2025
Global Live Attenuated Varicella Vaccine Market Research Report 2025
Paediatric Vaccine Market
Preventable Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Pediatric Vaccines Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Viral Vaccines Market Research Report 2025
Global Multivalent Vaccines Market Research Report 2025
Zoster Vaccine Live Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Inactivated Polio Virus Vaccine Market Research Report 2025
Measles Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global Measles and Rubella Vaccines Market Research Report 2025
Global Measles and Rubella MR Vaccine Market Research Report 2025
Aluminum based Vaccine Adjuvant Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Global GP Vaccination Market Research Report 2025
Influenza A Vaccine Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Tuberculosis Vaccine Drug Global Market Share and Ranking Overall Sales and Demand Forecast 2024 2030
Call
Buy Now
REQUEST FREE SAMPLE REPORT
Support Contacts
U.S. (TOLL FREE)
+1 (425) 388-2538
THE COMPANY
OUR PRODUCTS
CUSTOMER SUPPORT
POLICES
THE COMPANY
CUSTOMER SUPPORT
OUR PRODUCTS
POLICES
Copyright © 2018 Valuates.com. All Rights Reserved.
Sitemap - Privacy Policy - Terms & Conditions